On the other hand, EGFR mutant lung cancer is more immunologically “cold,” and while treatment with higher-generation targeted therapy (e.g., Osimertinib) is associated with greater overall survival and improved prognosis, immune checkpoint blockade responsiveness by such tumors is low (85). Here, EGFR is linked to lung carcinoma.